| __timestamp | MiMedx Group, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 49315000 |
| Thursday, January 1, 2015 | 133384000 | 75043000 |
| Friday, January 1, 2016 | 179997000 | 83749000 |
| Sunday, January 1, 2017 | 220119000 | 122682000 |
| Monday, January 1, 2018 | 258528000 | 207761000 |
| Tuesday, January 1, 2019 | 198205000 | 284812000 |
| Wednesday, January 1, 2020 | 181022000 | 317875000 |
| Friday, January 1, 2021 | 198359000 | 282660000 |
| Saturday, January 1, 2022 | 208789000 | 451421000 |
| Sunday, January 1, 2023 | 211124000 | 481871000 |
Cracking the code
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and MiMedx Group, Inc. over the past decade. From 2014 to 2023, MiMedx Group's SG&A expenses grew by approximately 133%, peaking in 2018. Meanwhile, Sarepta Therapeutics saw a staggering increase of over 870%, with a notable surge in 2022 and 2023.
This trend highlights Sarepta's aggressive expansion strategy, possibly linked to its innovative therapies and market penetration efforts. In contrast, MiMedx's steadier growth suggests a more conservative approach. Understanding these financial dynamics offers investors and industry analysts valuable insights into each company's strategic priorities and operational efficiency. As the biotech sector continues to evolve, monitoring such financial metrics will be key to predicting future market leaders.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Viatris Inc. and MiMedx Group, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Celldex Therapeutics, Inc. and MiMedx Group, Inc.